secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001576280-25-000135
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q1 revenue $203.5M (+21% YoY); raises FY2025 revenue guidance to $880-$890M
--------------------------------------------------------------------------------

- Q1 total revenue $203.5M, +21% YoY; oncology $150.6M (+20%, 59K tests); screening $5.7M (9K Shield tests); biopharma $45.4M (+21%).
- Net loss $95.2M ($0.77/sh) vs $115.0M loss year ago; non-GAAP net loss $61.1M ($0.49/sh); cash $803.9M.
- FY2025 revenue guidance raised to $880-$890M (+19-20% YoY) from $850-$860M; screening revenue guided $40-$45M (from $25-$30M).
- Non-GAAP gross margin guided 62-63%; FCF burn expected $225-$235M; ex-screening business on track for FCF breakeven in Q4 2025.
- Shield received CMS ADLT status ($1,495/test) and VA network coverage covering 9M lives; launched upgraded Guardant360 Tissue test.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000135/0001576280-25-000135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000135/gh-20250430.htm
  HTML page:      https://secwatch.observer/filing/0001576280-25-000135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer